<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The expression of the VAV proto-oncogene in 57 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> (CMD), B-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) and B-cell non-Hodgkin <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (B-NHL), and 61 with B-cell <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (B-CLL) was analysed </plain></SENT>
<SENT sid="1" pm="."><plain>VAV overexpression was observed in 19.5% of cases and 81% of VAV-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> also displayed VAV phosphorylation </plain></SENT>
<SENT sid="2" pm="."><plain>Overexpression was not observed in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> or CMD, but 13% of B-NHL and 34.4% of B-CLL patients (P = 0.002) overexpressed VAV </plain></SENT>
<SENT sid="3" pm="."><plain>The overexpression and phosphorylation of VAV was detected more frequently in 13q- <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (71.4%) versus other B-CLLs (23.4%, P = 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Overexpression of VAV protein is a frequent event in patients with B-CLL displaying loss of 13q sequences </plain></SENT>
</text></document>